Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1990 Dec 1;143(11):1177–1185.

Zidovudine (Retrovir) update.

A R Rachlis 1
PMCID: PMC1452857  PMID: 2224694

Abstract

Zidovudine (AZT) is the first antiretroviral agent to be licensed for the treatment of human immunodeficiency virus (HIV) infection. Since the initial placebo-controlled trial showing improved survival among patients with acquired immunodeficiency syndrome (AIDS) or symptomatic HIV infection (AIDS-related complex [ARC]) zidovudine has been evaluated in other stages of HIV infection. This review offers physicians who treat patients with HIV infection a comprehensive analysis of the current data on the clinical efficacy of zidovudine in various stages of HIV infection and on zidovudine's adverse effects. After a search of MEDLINE for pertinent articles published since 1985, controlled studies and studies of long-term zidovudine therapy, of zidovudine therapy for HIV-related conditions and of the incidence and management of adverse reactions were evaluated. In addition, abstracts from international meetings were reviewed. No significant difference in clinical outcome was found between high-dose and low-dose zidovudine therapy, but there were significantly fewer toxic effects in the low-dose group. In two other studies zidovudine was found to delay disease progression in patients with asymptomatic or mildly symptomatic HIV infection who had an absolute CD4 count of less than 0.5 x 10(9)/L; the low incidence of adverse reactions may have been due to either the early stage of the infection or the low dose used. The demonstration of zidovudine-resistant isolates after at least 6 months of therapy has yet to be correlated with clinical deterioration. When to begin zidovudine therapy among asymptomatic patients with a CD4 count of less than 0.5 x 10(9)/L remains unclear. Zidovudine can be used safely to delay progression to AIDS or ARC in certain patients with asymptomatic or mildly symptomatic HIV infection and can prolong survival in those with more severe infection. Further studies are necessary to identify indicators that could better define when to start treatment and how to alleviate toxic effects. Combination therapy with such agents as interferon alpha may become the preferred choice of therapy to prevent toxic effects and zidovudine resistance. Zidovudine prophylaxis has been used after HIV exposure. Although studies with animal models have had encouraging results infection has occurred despite immediate prophylaxis and thus further investigation is required.

Full text

PDF
1177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach M. C. Failure of zidovudine to maintain remission in patients with AIDS. N Engl J Med. 1989 Mar 2;320(9):594–595. doi: 10.1056/nejm198903023200913. [DOI] [PubMed] [Google Scholar]
  2. Bessen L. J., Greene J. B., Louie E., Seitzman P., Weinberg H. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N Engl J Med. 1988 Mar 17;318(11):708–708. doi: 10.1056/nejm198803173181113. [DOI] [PubMed] [Google Scholar]
  3. Chandrasekar P. H. Nail discoloration and human immunodeficiency virus infection. Am J Med. 1989 Apr;86(4):506–507. doi: 10.1016/0002-9343(89)90365-3. [DOI] [PubMed] [Google Scholar]
  4. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  5. Creagh-Kirk T., Doi P., Andrews E., Nusinoff-Lehrman S., Tilson H., Hoth D., Barry D. W. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988 Nov 25;260(20):3009–3015. [PubMed] [Google Scholar]
  6. Dalakas M. C., Illa I., Pezeshkpour G. H., Laukaitis J. P., Cohen B., Griffin J. L. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990 Apr 19;322(16):1098–1105. doi: 10.1056/NEJM199004193221602. [DOI] [PubMed] [Google Scholar]
  7. Don P. C., Fusco F., Fried P., Batterman A., Duncanson F. P., Lenox T. H., Klein N. C. Nail dyschromia associated with zidovudine. Ann Intern Med. 1990 Jan 15;112(2):145–146. doi: 10.7326/0003-4819-112-2-145. [DOI] [PubMed] [Google Scholar]
  8. Dubin G., Braffman M. N. Zidovudine-induced hepatotoxicity. Ann Intern Med. 1989 Jan 1;110(1):85–86. doi: 10.7326/0003-4819-110-1-85. [DOI] [PubMed] [Google Scholar]
  9. Edwards P., Turner J., Gold J., Cooper D. A. Esophageal ulceration induced by zidovudine. Ann Intern Med. 1990 Jan 1;112(1):65–66. doi: 10.7326/0003-4819-112-1-65. [DOI] [PubMed] [Google Scholar]
  10. Fiddian A. P. Preliminary report of a multicentre study of zidovudine plus or minus acyclovir in patients with acquired immune deficiency syndrome or acquired immune deficiency syndrome-related complex. J Infect. 1989 Jan;18 (Suppl 1):79–80. doi: 10.1016/s0163-4453(89)80084-2. [DOI] [PubMed] [Google Scholar]
  11. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  12. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  13. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  14. Fischl M., Galpin J. E., Levine J. D., Groopman J. E., Henry D. H., Kennedy P., Miles S., Robbins W., Starrett B., Zalusky R. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990 May 24;322(21):1488–1493. doi: 10.1056/NEJM199005243222103. [DOI] [PubMed] [Google Scholar]
  15. Gertner E., Thurn J. R., Williams D. N., Simpson M., Balfour H. H., Jr, Rhame F., Henry K. Zidovudine-associated myopathy. Am J Med. 1989 Jun;86(6 Pt 2):814–818. doi: 10.1016/0002-9343(89)90478-6. [DOI] [PubMed] [Google Scholar]
  16. Gill P. S., Rarick M., Brynes R. K., Causey D., Loureiro C., Levine A. M. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987 Oct;107(4):502–505. doi: 10.7326/0003-4819-107-4-502. [DOI] [PubMed] [Google Scholar]
  17. Helbert M., Fletcher T., Peddle B., Harris J. R., Pinching A. J. Zidovudine-associated myopathy. Lancet. 1988 Sep 17;2(8612):689–690. doi: 10.1016/s0140-6736(88)90506-5. [DOI] [PubMed] [Google Scholar]
  18. Helbert M., Robinson D., Peddle B., Forster S., Kocsis A., Jeffries D., Pinching A. J. Acute meningo-encephalitis on dose reduction of zidovudine. Lancet. 1988 Jun 4;1(8597):1249–1252. doi: 10.1016/s0140-6736(88)92072-7. [DOI] [PubMed] [Google Scholar]
  19. Henderson D. K., Gerberding J. L. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis. 1989 Aug;160(2):321–327. doi: 10.1093/infdis/160.2.321. [DOI] [PubMed] [Google Scholar]
  20. Henry K., Chinnock B. J., Quinn R. P., Fletcher C. V., de Miranda P., Balfour H. H., Jr Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA. 1988 May 27;259(20):3023–3026. [PubMed] [Google Scholar]
  21. Jacobson M. A., McGrath M. S., Joseph P., Molaghan J. B., Tadepalli S., Quinn R. Zidovudine-induced fever. J Acquir Immune Defic Syndr. 1989;2(4):382–388. [PubMed] [Google Scholar]
  22. Jacobson M. A., de Miranda P., Gordon S. M., Blum M. R., Volberding P., Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988 Aug;158(2):489–490. doi: 10.1093/infdis/158.2.489. [DOI] [PubMed] [Google Scholar]
  23. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  24. Kornhauser D. M., Petty B. G., Hendrix C. W., Woods A. S., Nerhood L. J., Bartlett J. G., Lietman P. S. Probenecid and zidovudine metabolism. Lancet. 1989 Aug 26;2(8661):473–475. doi: 10.1016/s0140-6736(89)92087-4. [DOI] [PubMed] [Google Scholar]
  25. Krown S. E., Gold J. W., Niedzwiecki D., Bundow D., Flomenberg N., Gansbacher B., Brew B. J. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1990 Jun 1;112(11):812–821. doi: 10.7326/0003-4819-112-11-812. [DOI] [PubMed] [Google Scholar]
  26. Lane H. C., Falloon J., Walker R. E., Deyton L., Kovacs J. A., Masur H., Banks S., Kirk L. E., Baseler M. W., Salzman N. P. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial. Ann Intern Med. 1989 Jul 1;111(1):41–50. doi: 10.7326/0003-4819-111-1-41. [DOI] [PubMed] [Google Scholar]
  27. Lange J. M., Boucher C. A., Hollak C. E., Wiltink E. H., Reiss P., van Royen E. A., Roos M., Danner S. A., Goudsmit J. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med. 1990 May 10;322(19):1375–1377. doi: 10.1056/NEJM199005103221907. [DOI] [PubMed] [Google Scholar]
  28. Langtry H. D., Campoli-Richards D. M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Apr;37(4):408–450. doi: 10.2165/00003495-198937040-00003. [DOI] [PubMed] [Google Scholar]
  29. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  30. Laskin O. L., de Miranda P., Blum M. R. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis. 1989 Apr;159(4):745–747. doi: 10.1093/infdis/159.4.745. [DOI] [PubMed] [Google Scholar]
  31. Lemp G. F., Payne S. F., Neal D., Temelso T., Rutherford G. W. Survival trends for patients with AIDS. JAMA. 1990 Jan 19;263(3):402–406. [PubMed] [Google Scholar]
  32. Liebes L., Mendoza S., Wilson D., Dancis J. Transfer of zidovudine (AZT) by human placenta. J Infect Dis. 1990 Feb;161(2):203–207. doi: 10.1093/infdis/161.2.203. [DOI] [PubMed] [Google Scholar]
  33. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Moss A. R., Bacchetti P. Natural history of HIV infection. AIDS. 1989 Feb;3(2):55–61. doi: 10.1097/00002030-198902000-00001. [DOI] [PubMed] [Google Scholar]
  35. Necrotising myopathy and zidovudine. Lancet. 1988 May 7;1(8593):1050–1051. [PubMed] [Google Scholar]
  36. Oksenhendler E., Bierling P., Ferchal F., Clauvel J. P., Seligmann M. Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Mar 1;110(5):365–368. doi: 10.7326/0003-4819-110-5-365. [DOI] [PubMed] [Google Scholar]
  38. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  39. Pottage J. C., Jr, Benson C. A., Spear J. B., Landay A. L., Kessler H. A. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. JAMA. 1988 Nov 25;260(20):3045–3048. doi: 10.1001/jama.260.20.3045. [DOI] [PubMed] [Google Scholar]
  40. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  41. Rooke R., Tremblay M., Soudeyns H., DeStephano L., Yao X. J., Fanning M., Montaner J. S., O'Shaughnessy M., Gelmon K., Tsoukas C. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989 Jul;3(7):411–415. doi: 10.1097/00002030-198907000-00001. [DOI] [PubMed] [Google Scholar]
  42. Routy J. P., Prajs E., Blanc A. P., Drony S., Moriceau M., Sarrazin C., Viallet F. Seizure after zidovudine overdose. Lancet. 1989 Feb 18;1(8634):384–385. doi: 10.1016/s0140-6736(89)91758-3. [DOI] [PubMed] [Google Scholar]
  43. Ruprecht R. M., O'Brien L. G., Rossoni L. D., Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine. Nature. 1986 Oct 2;323(6087):467–469. doi: 10.1038/323467a0. [DOI] [PubMed] [Google Scholar]
  44. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  45. Spear J. B., Benson C. A., Pottage J. C., Jr, Paul D. A., Landay A. L., Kessler H. A. Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy. J Infect Dis. 1988 Nov;158(5):1132–1133. doi: 10.1093/infdis/158.5.1132. [DOI] [PubMed] [Google Scholar]
  46. Steffe E. M., King J. H., Inciardi J. F., Flynn N. F., Goldstein E., Tonjes T. S., Benet L. Z. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Defic Syndr. 1990;3(7):691–694. [PubMed] [Google Scholar]
  47. Tavares L., Roneker C., Johnston K., Lehrman S. N., de Noronha F. 3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res. 1987 Jun 15;47(12):3190–3194. [PubMed] [Google Scholar]
  48. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  49. Wainberg M. A., Falutz J., Fanning M., Gill J., Gelmon K., Montaner J. S., O'Shaughnessy M., Tsoukas C., Ruedy J. Cessation of zidovudine therapy may lead to increased replication of HIV-1. JAMA. 1989 Feb 10;261(6):865–866. [PubMed] [Google Scholar]
  50. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  51. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES